.png){kind=icon}
.png){kind=icon}
Return
Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials
.png){kind=icon}
OA
AI
L
A
J
R
Á
M
S
H
D
E
L
M
M
S
O
B
J
K
L
S
Y
DOI：10.1093/bjd/ljag264.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Icotrokinra, a targeted oral peptide, precisely blocks the interleukin-23 receptor. In two phase 3 moderate-to-severe plaque psoriasis trials, ICONIC-ADVANCE 1 (NCT06143878) and ICONIC-ADVANCE 2 (NCT06220604), icotrokinra provided significantly higher skin clearance rates versus placebo at Week 16 and deucravacitinib at Week 16 and 24.
Journal
IF:
9.6
Papers:
2.8W
Citations:
3.2W
Organization
Cited Papers